The 'Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand' have been developed by the National Melanoma Working Group (NMWG) and MelNet in partnership with a wide range of sector experts and key stakeholders, including Te Aho o Te Kahu - Cancer Control Agency.
The statements describe what quality care for melanoma should look like in New Zealand based on current global best practice and will inform efforts to reduce the incidence and improve outcomes for melanoma patients and their families.
Te Aho o Te Kahu – Cancer Control Agency supports the use of the Quality Statements to Guide Melanoma Diagnosis and Care in New Zealand as a tool to guide clinical decision-making and promote best practice melanoma management in New Zealand.
Download the Quality Statements
Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand: Third edition
Current version: Effective from September 2023
Have feedback?
MelNet have committed to reviewing the Statements regularly, however feedback is welcome at any time to the MelNet Chief Executive. The next formal review will take place in 2025.
Learn more about the Quality Statements
Watch our six-part webinar series (based on 2nd edition)
More information on this webinar series can be found here.
Listen to the Goodfellow Unit podcast (recorded December 2023, based on 3rd edition)
Background
The document is an evolution of the Standards of Service Provision for Melanoma Patients in New Zealand – Provisional which were drafted by the National Melanoma Tumour Standards Working Group for the Ministry of Health in 2013.
The 'Quality Statements' were formally launched at the New Zealand Melanoma Summit held virtually on 12 - 13 February 2022. The NMWG reconvened in July 2022 and July 2023 with the purpose of reviewing the document to ensure the quality statements continued to reflect latest research and best practice. This resulted in the publication of the second edition in September 2022 and third edition in September 2023. This third edition builds on the previous versions, integrating additional sector feedback and incorporating new research and updates to best practice. Key changes to clinical content are noted in Appendix 5 of the document.
Interested in being part of the National Melanoma Working Group?
If you are interested in being part of the National Melanoma Working Group responsible for reviewing and updating the 'Quality Statements', please advise the MelNet Chief Executive.
Versions
Third edition: Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand. Current version: Effective from September 2023
Second edition: Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand Effective from October 2022 - August 2023
First edition: Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand Effective from November 2021 – September 2022
Endorsed by
